Активность фекальной β-глюкуронидазы у больных с воспалительными заболеваниями кишечника

Abstract

The aim of research: to investigate the activity of β-glucuronidase in coprofiltrates (OR feces) in patients with inflammatory bowel diseases - UC and CD at different severity levels (form of disease- mild, middle, severe) and to determine the significance as a laboratory criterion in the diagnosis, treatment and prognosis of IBD. Materials and methods. In research was prospectively studied 105 patients - 82 patients with IBD (29 patients with CD, 53 patients with UC) and 23 healthy volunteers without clinical laboratory indicators of inflammatory processes in the organism and diseases of the colon as the comparison group. The activity of β-glucuronidase in feces was determined using phenolphthalein glucuronide as a substrate. Results. The activity of β-glucuronidase in feces in patients with IBD did not differ from the healthy group (comparison group): in patients with IBD - 86.81 ± 8.4 μM / g / hr, and in norm, healthy group (comparison group) 76.04 ± 10.13 μM / g / hr (p> 0.05). Also we did not find significant differences in the activity of β-glucuronidase in patients with CD and UC, in comparison with the norm (healthy group), or between groups of patients with IBD (CD and UC). In both forms of IBD, we did not find significant differences in the activity of β-glucuronidase in patients with severe, mild or middle severity level of disease, as in comparison with healthy group so as between group of severity level. Conclusion. We have established that the activity of fecal β-glucuronidase in patients with different severity levels CD and UC did not differ from in patients of healthy group. Determination of the activity of fecal β-glucuronidasecan not use as objective laboratory criteria for determining the severity of IBD and predicting the course of the disease and, apparently, does not have essential value in the pathogenesis of IBD.